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Mutations within the granulin (GRN) gene that encodes progranulin (PGRN) cause the neurodegenerative
disease frontotemporal lobar degeneration with ubiquitin inclusions (FTLD-U). The receptor for PGRN in
the CNS has not been previously identified. In this issue of Neuron, Hu and colleagues identify Sortilin
(SORT1) as a key neuronal receptor for PGRN that facilitates its endocytosis and regulates PGRN levels
in vitro and in vivo.Encoded on human chromosome 17q21,
PGRN is a secreted glycoprotein that
has been shown to play roles in wound
repair, regulation of hair growth, tumori-
genesis, and inflammation (Bateman and
Bennett, 2009). PGRN can function either
as a full-length protein or as cleaved gran-
ulins (GRNs) (see Figure 1). GRNs are
derived from various cleavages of the
multiple cystinyl-rich repeats within the
full-length protein. The equilibrium
between PGRN and the GRNs can be
regulated in the periphery by elastase,
which cleaves PGRN toGRNs, and secre-
tory leukocyte peptidase inhibitor (SLPI),
which inhibits PGRN cleavage. Both
PGRN and GRNs play functional roles in
these aforementioned physiologic and
pathophysiologic processes, though
a precise understanding of the functional
roles of PGRN and GRNs both in the
periphery and in the central nervous
system (CNS) is lacking.
The importance of PGRN within the
CNS was not appreciated until 2006
when mutations in GRN were identified
as the cause of FTLD-U (reviewed in
Mackenzie et al., 2010). FTLD-U is a heri-
table neurodegenerative disease that
exhibits autosomal-dominant transmis-
sion and is pathologically characterized
by neuronal loss within, and atrophy of,
the frontal and temporal lobes of the
brain, and the intracellular accumulation
of ubiquitinated inclusion of the TAR
DNA binding protein (TDP-43) (reviewed
in Mackenzie et al., 2010). Although indi-
viduals with GRN mutations most often
present clinically with symptoms of frontal
temporal dementia (FTD), others present
with symptoms that resemble Alzheimerdisease (AD), Lewy Body disease, and
corticobasilar syndrome with ages
ranging from 35–89. Approximately 50
identified mutations have been identified
in GRN that are linked to FTD or related
disorders (Mackenzie et al., 2010). Many
of the mutations inGRN are hypothesized
to lead to disease through haploinsuffi-
ciency as they lead to sequence frame-
shifts and premature stop codons, which
result in nonsense-mediated mRNA
decay of themutant transcript. Consistent
with this, 50% or greater reductions of
PGRN levels have been documented in
patients with certain GRN mutations.
Recent data from Wang and colleagues
suggest that certain cysteine mutations
preserve normal PGRN levels but impair
the conversion of PGRN to GRNs in vitro
and reduce neurite-stimulating activity of
PGRN in culture (Wang et al., 2010). In
addition to its causative role in FTLD-U,
PGRN may play a role in modifying other
degenerative CNS disorders. Variants in
GRN have been associated both with
age of onset and survival of individuals
with amyotrophic lateral sclerosis (ALS)
and through haplotype analysis with risk
for primary progressive multiple sclerosis
in males (Fenoglio et al., 2010; Sleegers
et al., 2008).
Since the discovery of GRN mutations,
the published literature on PGRN has
grown from 18 publications to over 240,
with many of these focusing on the role
of PGRN within the CNS. Despite this
wave of research, there is little consensus
on the normal and pathological roles of
PGRN or GRNs within the CNS. PGRN
can function asa nervegrowth, protective,
or survival factor (Bateman and Bennett,Neuron 68, N2009); these roles would be consistent
with the presentation of neurodegenera-
tion upon partial loss of PGRN function.
Although PGRN is expressed in neurons,
the primary source of PGRN in the CNS
appears to be from activated microglia.
In this issue of Neuron, Hu et al. (2010)
have made a key advance by identifying
Sortilin (SORT1) as a major neuronal
receptor for the PGRN protein. This
discovery provides a critical mechanistic
link that could help the field to understand
normal CNS functions of PGRN and how
partial loss of PGRN function may lead to
neurodegenerative disease. Importantly,
they show that Sortilin regulates PGRN
levels, providing an insight that may turn
out to have therapeutic relevance.Notably,
the authors utilized an unbiased, expres-
sion cloning approach to identify binding
partners for an alkaline phosphatase-
tagged PGRN ligand. This methodology
was similar to that employed by this group
to identify prion protein as the receptor for
an Ab oligomer (Laure´n et al., 2009). Of
225,000 clones screened, Sortilin was the
only high-affinity binding partner identified,
and binding studies in neurons from
Sortilin/ mice demonstrate that Sortilin
is themajor receptor for PGRN on cultured
neurons (Hu et al., 2010).
Sortilin is a member of a family of
cellular vps10p type 1 receptors ex-
pressed largely in neurons (Willnow
et al., 2008). Given the potential for func-
tional overlap and previous associations
of related Vps10 family members with
AD and the functional impact of these
proteins on APP processing, the authors
performed a number of studies to demon-
strate that PGRN binds only Sortilin andovember 18, 2010 ª2010 Elsevier Inc. 601
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Figure 1. Sortilin Is a PGRN Receptor
(A) PGRN is cleaved into GRNs by elastase and blocked by SLPI.
(B) Sortilin is a VPS10p receptor. PGRN and NT have overlapping binding sites, whereas proNGF binds to
a distinct site.
(C) Binding of PGRN to Sortilin (1) results in endocytosis (2) of the complex. PGRN is delivered to the
lysosome and Sortilin is recycled to the plasma membrane (3).
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has a number of ligands. It binds the
neuropeptide neurotensin (NT) within the
tunnel of a ten-bladed b-propeller domain,
and is a coreceptor for proneurotrophin
through a specific linear sequence of the
ectodoman. In the current manuscript
the authors show that NT and PGRN likely
bind Sortilin through a common site. The
last six residues of NT compete for
PGRN binding to Sortilin. Notably, the C
terminus of PGRN containing the GRN-E
domain appears sufficient to bind Sortilin.
In contrast, proNGF inhibited the binding
of PGRN to Sortilin only at high concentra-
tions and direct binding studies indicated
that proNGF and PGRN bound distinct
sites on the Sortilin ectodomain. In
comparison to the other GRNs, GRN-E
contains several specific and conserved
amino acid differences, and this sequence
variation may underlie the failure of the
PGRN lacking GRN-E to bind Sortilin
(Hoque et al., 2005).
Because genetically caused reductions
in PGRN levels are associatedwith human602 Neuron 68, November 18, 2010 ª2010 Edisease, the authors further explored the
functional impact of Sortilin on PGRN
levels. Coexpression studies in HEK293T
cells showed that Sortilin reduces levels
of PGRN in the media, and provide
evidence that Sortilin rapidly endocytoses
PGRN and delivers it to the lysosome,
similar to its known function for other
proteins. Of interest, expression of the
ectodomain responsible for the binding
of Sortilin to PGRN did not alter secreted
PGRN levels, a somewhat surprising
result because often expression of
a soluble receptor will stabilize the
cognate ligand and increase its extracel-
lular levels. Even more striking was that
mice lacking Sortilin had elevated brain
and serum PGRN, and that mice lacking
Sortilin and one PGRN allele had PGRN
levels similar to those observed in wild-
type mice. Thus, Sortilin appears to
control PGRN levels in mice, but there is
no evidence that the converse is true.
Indeed, Sortilin immunoreactivity does
not appear to be altered in patients with
FTLD-U.lsevier Inc.To examine the interaction between
Sortilin and PGRN in a more dynamic
in vivo setting, the authors evaluated
these proteins in the lumbar spinal cord
following sciatic nerve injury. PGRN was
upregulated following axotomy, but this
elevation was attributable to increased
expression by microglia. These data
suggest that PGRN is secreted by micro-
glia and then binds neuronal Sortilin. To
support this assertion, the authors
tracked mCherry-tagged PGRN and
GFP-tagged Sortilin to demonstrate that
exogenous PGRN binds Sortilin, colocal-
izes with Sortilin in endocytic vesicles,
and eventually colocalizes with Lamp1,
a marker for lysosomes, but Sortilin is
rapidly recycled back to the cell surface
(Figure 1). These data together with the
surprising finding that mice lacking
PGRN develop accelerated lipofuscino-
sis, a condition that is consistent with
lysosomal dysfunction, potentially impli-
cate a normal role of PGRN in the lyso-
some (Ahmed et al., 2010). They also
provide another speculative link to accu-
mulation of ubiquitinated TDP-43, which
is the defining pathological feature of
FTLD-U (reviewed in Mackenzie et al.,
2010).
This study provides a crucial bridge
between secreted PGRN and neurons.
At least in mice, interaction of secreted
PGRN and Sortilin appears to regulate
PGRN levels (Hu et al., 2010). If Sortilin
is indeed the major receptor for PGRN,
then a logical inference would be that
PGRN-Sortilin or GRN-E-Sortilin interac-
tion also mediates some of the functional
effects of PGRN on neuronal growth and
survival, though this will need to be exper-
imentally determined. Though the study
certainly provides a great deal of evidence
that Sortilin is a major neuronal PGRN
receptor, it does not exclude the possi-
bility that other receptors may play a role
in mediating the biological effects of
PGRN. Though elegantly employed to
identify Sortilin as a PGRN receptor,
expression cloning might miss complex
receptors that are encoded by multiple
proteins and receptors encoded by very
large cDNAs that might be underrepre-
sented or absent in the cDNA expression
library used. Another question not
addressed in this study is the role of
receptors on other cell types in mediating
PGRN levels and functions.
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PreviewsAs the authors note, a key issue in
FTLD-U is whether PGRN haploinsuffi-
ciency causes disease through reduction
in the levels of PGRN, GRNs, some other
processed fragment, or some combina-
tion of these. At least in the periphery
there is some data that indicates that
PGRN and GRNs may have distinct func-
tions (Bateman and Bennett, 2009).
Unfortunately, the tools to track PGRN
processing into GRNs are currently not
well-developed. The issue of the relation-
ship between PGRN and GRNs is critical
when thinking about the therapeutic impli-
cations of this and other studies that only
track PGRN levels. Increasing PGRN
levels could decrease GRNs levels, and
if loss of GRNs is more closely linked to
disease, then one might actually worsen
the disease rather than make it better.
Speculatively, one might wonder whether
Sortilin-mediated trafficking of PGRN
results in processing of it into functional
GRNs or other novel fragments. Another
therapeutic implication is that PGRN-
mediated signaling through Sortilin could
play a role in FTLD-U; if this is the case,
then restoring that signaling could be
a tractable therapeutic strategy. Given
the competitive binding between NT and
PGRN, NT or NT agonists might be inter-
esting agents to explore for their effects
on PGRN in vivo. Identification of Sortilinas a major neuronal PGRN receptor may
also have implications for understanding
PGRN function in wound healing. Sortilin
is mainly expressed in neurons, but it is
also expressed in keratinocytes (Kiss
et al., 2010). Thus, it is certainly logical
to explore whether Sortilin mediates
PGRN effects in wound healing.
Neither young nor aged PGRNor Sortilin
knockout mice demonstrate phenotypes
that truly mimic FTLD-U (Ahmed et al.,
2010; Jansen et al., 2007). Nor in the
current work does loss of PGRN or Sortilin
appear to increase neuronal loss to periph-
eral axotomy. PGRN+/ mice also appear
phenotypically normal. Thus, the link
between PGRN haploinsufficiency, neuro-
degeneration, and TDP-43 pathology
remainsmysterious. Alongwith the paucity
of tools to study GRNs in vivo, the lack of
animal models that phenocopy the human
disease presents a major translational
barrier to investigations of the PGRN-
TDP-43 axis. Despite these biological
limitations, this study breaks new ground
and opens up new biological pathways
that unequivocally link PGRN and Sortilin.REFERENCES
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